Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

PUBLICATIONS (JANUARY 1, 2004-DECEMBER 31, 2004)

on

  • 846 views

 

Statistics

Views

Total Views
846
Views on SlideShare
846
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

PUBLICATIONS (JANUARY 1, 2004-DECEMBER 31, 2004) PUBLICATIONS (JANUARY 1, 2004-DECEMBER 31, 2004) Document Transcript

  • Department of Oncology Appendix II: Publications January-December 2005 PUBLICATIONS Cancer Prevention Program Michael Pollak Canil CM., Moore, MJ., WInquist, E., Baetz, T., Pollak, M., Chi, KN., Berry, S., Ernst, DS., Douglas, L., Brundage, M., Fisher, B., McKenna, A., Seymour, L. Randomized Phase II study of two dose of Gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trial Group. Journal of Clinical Oncology 23: 455-60, 2005. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin- like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers & Prevention 3: 699-704, 2005. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood precessing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on caroteniods, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiology, Biomarkers & Prevention 14: 727-730, 2005. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers & Prevention 14: 850-855, 2005. Nam, R.K., Trachtenberg, J., Jewitt, M.A.S., Toi, A., Evans, A., Narod, S.A., Pollak, M. Serum insulin-like growth factor-1 (IGF-1) levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-1 physiology and prostate cancer risk. Cancer Epidemiology, Biomarkers & Prevention 14: 1270-1273, 2005. Diorio, C., Pollak, M., Byrne, C., Masse, B., Hebert-Croteau, N., Yaffe, M., Cote, G., Berube, S., Morin, C., Brisson, J. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiology, Biomarkers & Prevention 14: 1065-1073, 2005. Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 14: 1402-1410, 2005. Platz, E.A., Pollak, M.N., Leitzmann, M.F., Stampfer, M.J., Willett, W.C., Giovannucci, E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control. 16: 255-262, 2005. 1
  • Department of Oncology Appendix II: Publications January-December 2005 Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE.Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292, 2005. Camirand, A., Zakikhani, M., Young, F., Pollak, M. Inhibition of insulin-like growth factor-1 receptor signaling enhances the effect of ZD 1839 (Gefitinib, Iressa) on growth inhibition and apoptosis induction in human breast cancer cells. Breast Cancer Research 7: R570-R579, 2005. Majeed, N., Blouin, M-J., Kaplan-Lefko, P.J., Barry-Shaw, J., Greenberg, N.M., Gaudreau, P., Bismar, T.A., Pollak, M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24: 4736-4740, 2005. Berube, S., Diorio, C., Masse, B, Herbert-Croteau, N., Byrne, C., Cote, G., Pollak, M., Yaffe, M., Brisson, J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 14: 1553-1559, 2005. Pinheiro, S.P., Holmes, M.D., Pollak, M.N., Barieri, R.L., Hankinson, S.E. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 14: 2147-2153, 2005. Kucab, J.E., Lee, C., Chen, C.H., Zhu, J., Gilks, C.B., Cheang, M., Huntsman, D., Yorida, E., Emerman, J., Pollak, M., Dunn, S.E. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 7: R796-807, 2005. Levitt, R.J., Georgescu, M.M., Pollak, M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun. 336: 1056-1061, 2005. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Brisson J. Levels of C-peptide and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 14: 2661-2664. 2005. Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging. [Epub ahead of print] 2
  • Department of Oncology Appendix II: Publications January-December 2005 Cancer Genetics Program William Foulkes Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Møller P, Maehle L, Badzioch M, The Cancer Research UK/British Association of Urological Surgeons’ Section of Oncology Collaborators, Eeles RA, Easton DF, English DR, Southey M, Hopper JL, Foulkes WD, Giles GG. Macrophage Scavenger Receptor 1 (MSR1) 999C>T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol Biomark Prevent, 14: 397-402, 2005 (WDF is corresponding author). Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McClennan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Obstet Gynecol Sur, 60 (4): 235-6, 2005. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McClennan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers corresponding. Gynecol Oncol, 96 (1): 222-6, 2005. Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, Brunet JS,Porter P, Foulkes WD. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol, 16 (5): 735-742, 2005. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA. A Basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev, 14 (5): 1108-12, 2005. Makriyianni I, Hamel N, Ward S, Foulkes WD, Graw S. BRCA1:185delAG found in the San Luis Valley probably originated in a Jewish founder. J Med Genet, 42 (5): e27, 2005 (WDF is corresponding author). Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res, 11(11): 4003-11, 2005. Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim- Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev, 14 (6): 1534-8, 2005. 3
  • Department of Oncology Appendix II: Publications January-December 2005 Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes WD, Chan M, Turner F, Bishop DT. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer, 15: 104 (4): 719-29, 2005. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S,Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey- Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon- Albright LA, Seminara D; ACTANE Consortium. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet, 77 (2): 219-29, 2005. Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control, 16 (6): 667-674, 2005. McVety S, Younan R, Li L, Gordon PH, Wong N, Foulkes WD, Chong G. Novel genomic insertion-- deletion in MLH1: possible mechanistic role for non-homologous end-joining DNA repair. Clin Genet, 68 (3): 234-238, 2005. Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 7 (5): R833-R843, 2005. Sun S, Greenwood CM, Thiffault I, Hamel N, Chong G, Foulkes WD. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. J Med Genet, 42 (10): 766-768, 2005. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol, 23 (30): 7491-6, 2005. 4
  • Department of Oncology Appendix II: Publications January-December 2005 Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S, Pasini B, Ainsworth P, Gershoni- Baruch R, Foulkes WD, Klijn J, Tung N, Rennert G, Olopade O, Couch F, Wagner T, Olsson H, Sun P, Weitzel JN, Narod SA. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer, 117 (6): 988-91, 2005. Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol, 23 (30): 7503-11, 2005. van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes WD, Lynch H, Burn J, Moslein G, Fodde R. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer, 44 (2): 123-38, 2005. Raquel Aloyz Cesaire R, Oliere S, Sharif-Askari E, Loignon M, Lezin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, Panasci L, Bell JC, Hiscott J. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene, 25:349-58, 2006. Xu Z.Y., Han F.Y., Panasci L., Aloyz R.XRCC3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase check point activation, and reduced apoptosis. J. Pharmacology and Experimental Therapeutics, 314:495-505, 2005. Marc Tischkowitz An Assessment of the Efficacy of Cancer Genetic Counseling Using Real-time Videoconferencing Technology (Telemedicine) Compared to Face-to-Face Consultations. Jordanna Joaquina Coelho, Angela Arnold, Jeremy Naylor, Marc Tischkowitz and James MacKay. European Journal of Cancer. 2005;41 2257-2261. A common Fanconi anaemia mutation in Black populations of Sub-Saharan Africa. Neil V Morgan, Fahmida Essop, Ilja Demuth, Thomy de Ravel, Stander Jansen, Marc Tischkowitz, Cathryn M Lewis, Linda Wainwright, Janet Poole, Hans Joenje, Martin Digweed, Amanda Krause & Christopher G Mathew. Blood. 2005 1;105(9):3542-4. Nijmegen breakage syndrome diagnosed as Fanconi anaemia. H. V. New, C.M. Cale, M. Tischkowitz, B. Flores De Laurnaga, A. Jones, P.Telfer, P. Veys, A. D’Andrea, C.G. Mathew, and I. Hann. Pediatric Blood and Cancer 2005;44(5):494-9 5
  • Department of Oncology Appendix II: Publications January-December 2005 A common founder mutation in FANCA underlies the world highest prevalence of Fanconi anemia in Gypsy families from Spain. Elsa Callén, José A. Casado, Marc D. Tischkowitz, Juan A. Bueren, Amadeu Creus, Ricard Marcos, Angeles Dasí, Jesús M. Estella, Arturo Muñoz, Juan J. Ortega, Johan de Winter, Hans Joenje, Detlev Schindler, Helmut Hanenberg, Shirley V. Hodgson, Christopher G. Mathew, Jordi Surrallés. Blood 2005 Mar 1;105(5):1946-9 Patricia Tonin Presneau N, Shen Z, Provencher D, Mes-Masson A-M, Tonin PN. 2005. Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol. 26: 1621-27. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson A-M. 2005. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672-87. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson A-M, Tonin PN. 2005. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2 Mol Carcinog 43: 141-54. Arcand SL, Provencher D, Mes-Masson A-M, Tonin PN. 2005 OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. Int J Oncol. 5:1315-20. Hematology/Oncology Carlo Gambacorti-Passerini Piazza R, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, Gambacorti- Passerini C. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukemic cells obtained from patients resistant to Imatinib. Leukemia, 19, 132-134, 2005. Gambacorti-Passerini C. Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib. Haematologica 2005;90:434. Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Expression, purification and inhibition of human RET tyrosine kinase. Protein Expression & Purification, 41, 177-85, 2005. Gunby RH, Tartari C, Donella-Deana A, Mologni L, Francesca Porchia, Leonardo Scapozza, Carlo Gambacorti-Passerini. Enzyme-Linked Immunosorbent Assay for screening inhibitors of the oncogenic Anaplastic Lymphoma Kinase. Haematologica, 90, 988-90, 2005. 6
  • Department of Oncology Appendix II: Publications January-December 2005 Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Tartari C, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna L. Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry, 44, 8533-42, 2005. Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets. 2005 Jun;9(3):515-32. Gambacorti-Passerini C, Gasser M, Assouline S, Scapozza L. BMS-354825 binding mode in Ableson kinase revealed by molecular docking studies. Leukemia, 19, 1267- 1269, 2005. Piazza R, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Imatinib dose increase up to 1200 mg daily can induce durable complete cytogenetic remissions (CCR) in relapsed Ph+ chronic myeloid leukemia (CML) patients. Leukemia, 2005, 19, 1985–1987. R G Piazza, V Magistroni, A Franceschino, C Gambacorti-Passerini. ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients'. Response to Leguay et al, Leukemia 19, 2005, 2333-2334. Susan Solymoss Kahn SR, Kearon C, Julian JA, Mackinnon B, Kovacs MJ, Wells P, Crowther MA, Anderson P, van Nguyen P, Demers C, Solymoss S, Kassis J, Geerts W, Rodger M, Hambleton J, Ginsberg JS: Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005; 3: 718-23. Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I: Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med. 2005; 165: 1173-1178. McGill Programs in Whole Person Care Balfour Mount and Thomas Hutchinson Hutchinson T. Healing and palliative care in end stage renal disease. Palliative Medicine. 2005; 19: 270-277. Hutchinson TA. Transitions in the lives of patients with end stage renal disease: a cause of suffering and an opportunity for healing. Palliative Medicine 2005; 19: 270-277. Chater S, Hutchinson T, and Seely JF. Advanced renal disease and discontinuation of dialysis. In MacDonald N, Hagen N and Oneschuk D eds. Palliative medicine – a case- based manual, 2nd edition, Oxford University Press, 2005. 7
  • Department of Oncology Appendix II: Publications January-December 2005 Mount BM. Spiritual Care. In MacDonald N, Hagen N and Oneschuk D eds. Palliative medicine – a case-based manual, 2nd edition, Oxford University Press, 2005. Basic Cancer Research Nicole Beauchemin Insulin Acutely Decreases Hepatic Fatty Acid Synthase Activity. S.M. Najjar, Y. Yang, M.A. Fernstrom, G.A. Abou-Rjaily, A.M. DeAngelis, Q.Y Al-Share, T. A. Miller, T. Dai, S. Ratnam, R.J. Ruch, S. Smith, S.H. Lin, N. Beauchemin and A.M. Oyarce. Cell Metabolism 2, 43-53 (2005). Pnina Brodt Yakar S., LeRoith D. and Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression:lessons from animal models. Cytokine and Growth Factor Reviews 16:407-420, 2005 *Khatib, A.-M., August P., Fallavollita, L., Wang N., Samani A., Kontogiannea M, Meterissian S. and Brodt P. Characterization of the host pro-inflammatory response to tumor cells during the initial stages of liver metastasis. Am. J. Pathol. 167:749-59, 2005 Terry Chow Sibgat A. Choudhury, and Terry Y-K. Chow, DNA repair protein: The endo- exonuclease as a new front in cancer therapy. Future Oncology 1(2):265-271, 2005. Belzile, J-P, Choudhury, SA, Cournoyer, D, and Chow, TYK. Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy. Current Gene Therapy 6(1):111-123, 2006. George Shenouda, Amira Mehio, Luis Souhami, Marie Duclos,Lorraine Portelance, Alexandre Belenkov and Terry Chow. Eurthropoietin receptor expression in biopsy specimens from patients with uterine cervix squamous cell carcinoma. 2006. Int. J. Gynecol. Cancer 16:752-756. Mark Featherstone Huang, H., Rastegar, M., Bodner, C., Goh, S.-L., Rambaldi, I. and Featherstone, M. 2005. MEIS C-termini harbor transcriptional activation domains that respond to cell signaling. J. Biol. Chem. 280, 10119-10127. Antonis Koromilas Fillebeen C, Rival Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, Koromilas AE* and Pantopoulos K* (2005) Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus. J Biol Chem. 280:9049-57 * Corresponding authors Pluquet O, Qu LK, Baltzis D and Koromilas AE 2005 Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and GSK-3β. Mol. Cell. Biol.25: 9392-9405. 8
  • Department of Oncology Appendix II: Publications January-December 2005 Alain Nepveu Gingras, H., M. Krasilnikova, G. Bérubé, and Alain Nepveu. (2005) Biochemical Characterization of the Mammalian Cux 2 Protein. Gene 344: 273-285. Santaguida, M, and A. Nepveu. (2005) Differential Regulation of CDP/Cux p110 by Cyclin A/cdk2 and Cyclin A/cdk1. Journal of Biological Chemistry 280:32712-32721. Jerry Pelletier Fukamiya, N., Lee, K.-H., Muhammad, I., Murakami, C., Okano, M., Harvey, I., and Pelletier, J. (2005). Structure-activity relationships of quassinoids for eukaryotic protein synthesis. Canc. Lett. 220, 37-48. Malina, A., Khan, S., Carlson, C.B., Svitkin, Y., Harvey, I., Sonenberg, N., Beal, P., and Pelletier, J. (2005). Inhibitory properties of nucleic acid-binding ligands on protein synthesis. FEBS Lett. 579, 79-89. Prawitt, D., Enklaar, T., Gartner-Rupprecht, B., Spangenberg, C., Fees, S., Lucito, R., Reutzel, D., Brozek, I., Limon, J., Pelletier, J., and Zabel, B. (2005). Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proc. Natl. Acad. Sci USA 102, 4085-4090. Kwan, T., Liu, J., Dubow, M., Gros, P., Pelletier, J. (2005) The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc. Natl. Acad. Sci USA 102, 5174-5179. Hamdan, F.F., Audet, M., Garneau, P., Pelletier, J., and Bouvier, M. (2005). High- throughput screening of G protein-coupled receptors antagonists using a BRET1-based β- arrestin2 recruitment assay. J. Biomolecular Screening. 10, 463-475. Park, E., Lee, J.M., Blais, J.D., Bell, J.C., and Pelletier, J. (2005). Internal translation initiation mediated by the angiogenic factor Tie2. J. Biol. Chem. 280, 20945-20953. Bordeleau, M.-E., Matthews, J., Wojnar, J.M., Lindqvist, L., Novac, O., Jankowsky, E., Sonenberg, N., Northcote, P., Teesdale-Spittle, P., and Pelletier, J. (2005) Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl. Acad. Sci. USA 102, 10460-10465. Yan, Y., Svitkin, Y., Lee, J.M., Bisaillon, M., and Pelletier, J. (2005). Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 11, 1238-1244. Stephane Richard Larocque, D., A. Galarneau, H. Liu, G. Almazan and S. Richard. 2005. p27Kip1 mRNA protection by QUAKING RNA binding proteins promote oligodendrocyte differentiation. Nature Neuroscience 8:27-33 9
  • Department of Oncology Appendix II: Publications January-December 2005 Richard, S., M. Morel and P. Cléroux. 2005. Arginine methylation regulates IL-2 gene expression: A role for PRMT5. Biochemical Journal 388:379-386 Boisvert, F.-B. U. Déry, J.-Y. Masson and S. Richard. 2005. Arginine methylation of MRE11 by PRMT1 is required for the intra-S-phase DNA damage checkpoint. Genes & Development 19:671-676 Boisvert, F.M. M.J. Hendzel, J.Y. Masson and S. Richard. 2005. Methylation of MRE11 regulates it intranuclear compartmentalization. Cell Cycle 4:981-989 Côté. J. and S. Richard. 2005. Tudor domain bind symmetrical dimethylated arginines. Journal of Biological Chemistry 280:28476-83 Galarneau, A. and S. Richard. 2005. Target RNA motif and target mRNAs identified for the QUAKING STAR protein. Nature Structural & Molecular Biology 12:691-8 Boisvert, F.-M., Chénard, C.A. and S. Richard. 2005. Protein interfaces in signaling regulated by arginine methylation. Science STKE 271:re2 pages 1-10. Bedford, M.T and S. Richard. 2005. Arginine methylation: an emerging regulator of protein function. Molecular Cell 18:263-272. Lukong K.E., D. Larocque, A.L. Tyner and S. Richard (2005) The intranuclear localization of Sam68 is regulated by BRK tyrosine phosphorylation. Journal of Biological Chemistry 280:38639-47 Citation index: 6.5, times cited 0 Boisvert, F.-M., A. Rhie and S. Richard and A. Doherty (2005) The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA Binding activity Cell Cycle 4:1834-41. Richard, S., N. Torabi, G.Valverde-Franco, G. A.Tremblay, T. Chen, G. Vogel, M. Morel, P. Cléroux, A. Forget-Richard, S. Komarova, M. L. Tremblay, W. Li, A. Li, Y. J. Gao and J. E. Henderson (2005) Ablation of the Sam68 RNA binding protein protects mice from age-related bone loss. PLoS Genetics, Dec 16;1(6):e74, pp1-13. Uri Saragovi Tyurina YY, Nylander KD, Mirnics ZK, Portugal C, Yan C, Zaccaro C, Saragovi HU, Kagan VE, Schor NF. The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell. 2005 4:187-96. Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 2005 24:350-8. Li S, Saragovi HU, Nedev H, Zhao C, Racine RJ, Fahnestock M. Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis. Mol Cell Neurosci. 2005 29:162-72. 10
  • Department of Oncology Appendix II: Publications January-December 2005 Mirnics ZK, Yan C, Portugal C, Kim TW, Saragovi HU, Sisodia SS, Mirnics K, Schor NF. P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiol Dis. 2005 20(3):969-85. Yan C, Mirnics ZK, Portugal CF, Liang Y, Nylander KD, Rudzinski M, Zaccaro C, Saragovi HU, Schor NF. Cholesterol biosynthesis and the pro-apoptotic effects of the p75 nerve growth factor receptor in PC12 pheochromocytoma cells. Brain Res Mol Brain Res. 2005; 139(2):225-34. M. Rudzinski and H. Uri Saragovi. Glaucoma: validated and facile in vivo experimental models of a chronic neurodegenerative disease for drug development. 2005. Current Med. Chem. 5:43-49 Maria Clara Zaccaro, Hong Boon Lee, Mookda Pattarawarapan, Zebin Xia, Antoine Caron, Kevin Burgess, and H. Uri Saragovi. SAR of Agonistic Small Molecule Peptidomimetic Ligands of TrkA and of TrkC Receptors. 2005, Chemistry and Biology. 12(9):1015-28. H. Uri Saragovi. Strategies, Molecular Targets and Animal Models Useful for Developing Therapies for Alzheimer’s Disease. 2005. Current Med. Chem. (Editorial) 5:1-3. H. Uri Saragovi. Progression of age-associated cognitive impairment correlates with quantitative and qualitative loss of TrkA receptor protein in NB and cortex. 2005. J. Neurochem. 95(5):1472-80. Hinyu N. Nedev; Guy Klaiman; Andrea LeBlanc, and H. Uri Saragovi. Synthesis and evaluation of novel dipeptidyl benzoyloxymethyl ketones as caspase inhibitors. 2005. Biol. Bioch, Res, Com. 336(2):397-400. Thomas MS, Zhang W, Jordan PM, Saragovi HU, Taglialatela G. Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells. J Neuroinflammation. 2005; 6;2:19. Reviews H. Uri Saragovi. Strategies, Molecular Targets and Animal Models Useful for Developing Therapies for Alzheimer’s Disease. 2005. Current Med. Chem. (Editorial). Jian Hui Wu Wu, J.H.; Miao, W.M.; Hu, L.G. and Batist, G. Chemical Modulators of Keap1/Nrf-2 interaction as Chemoprevention Agents. Era of Hope Department of Defense Breast Cancer Research Program Meeting 2005 Proceedings:299. 11
  • Department of Oncology Appendix II: Publications January-December 2005 Maria Zannis-Hadjopoulos Miccoli, L., Frouin, I., Novac, O., Di Paola, D., Harper, F., Zannis-Hadjopoulos, M., Maga, G., Biard, D.S. and Angulo, J.F. (2005). The human stress-activated protein, kin17, belongs to the the multiprotein DNA replication complex and associates in vivo with mammalian replication origins. Mol. Cell. Biol. 25: 3814-3830. Sibani, S., Price, G. B. and Zannis-Hadjopoulos, M. (2005). Decreased origin usage and initiation of DNA replication in haploinsufficient HCT116 Ku80+/- cells. J. Cell Sci., 118: 3247- 3261. Sibani, S., Price, G. B. and Zannis-Hadjopoulos, M. (2005). Ku80 binds to human replication origins prior to the assembly of the ORC complex. Biochemistry 44(21):7885-7896. Invited Review (Peer-reviewed): Zannis-Hadjopoulos, M. and Price, G.B. (2005). DNA replication. In: Encyclopedia of Life Sciences, John Willey & Sons, Ltd.; Chichester, UK Radiation Oncology Carolyn Freeman Roberge, D., Kun, L.E. and Freeman, C.R. Intracranial germinoma: on whole ventricular irradiation. Pediatric Blood & Cancer 2005; 44:358-362. Niazi, T.M., Souhami, L., Sultanem, K., Duclos, M., Shenouda, G., Freeman, C. Long- term results of para-aortic irradiation for patients with stage I seminoma of the testis. . International Journal of Radiation Oncology, Biology and Physics 2005; 61:741-744 Davis, A.M., O’Sullivan, B., Turcotte, R, Bell, R.S., Catton, C., Chabot, P., Wunder, J.S., Hammond, A, Benk, V., Kandel, R.A., Goddard, K., Freeman, C., Sadura, A., Zee, B., Day, A., Dongsheng, T. and Pater, J.L., Late radiation morbidity following preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiotherapy and Oncology 2005; 75:48-53 Greenberg, M.L., Fisher, P.G., Freeman, C, Koronas, D.N., Bernstein, M., Friedman, H., Blaney,S., Hershon, L., Zhou, T., Chen, Z.,., Kretschmar, C. Etoposide, Vincristine, and Cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: A Pediatric Oncology Group phase I study. Pediatric Blood & Cancer 2005; 45:644-648. Al-Yahya, K., Schwartz, M., Shenouda, G., Verhaegen, F., Freeman, C.R., Seuntgens, J. Energy modulated electron therapy using a few leaf electron collimator in combination with IMRT and 3D-CRT: Monte Carlo-based planning and dosimetric evaluation. Medical Physics 2005; 32:2976-2986 12
  • Department of Oncology Appendix II: Publications January-December 2005 Book chapters Freeman, C.R., Farmer, J-P. Brain Stem Tumours. In: Pediatric CNS Tumours. Clinics in Developmental Medicine. MacKeith Press, London. E.J. Estlin and S. Lowis, (eds). Chapter 12, pp 234-244, 2005. Shirley Lehnert A novel non-toxic camptothecin formulation for cancer chemotherapy. M. Berrada, A. Serreqi, A. Owusu, A. Gupta and S. Lehnert* Biomaterials 26: 2115-2120, 2005. Relative biological effectiveness of interstitial Iodine-125 and external beam radiation measured in a mouse tumor model. Shirley Lehnert*, Brigitte Reniers, Frank Verhaegen Int. J.Radiat. Oncol. Biol. Phys. 63: 224-229, 2005 Thierry Muanza Muanza T, Cotrim A, Sowers A, Baum B, Cook J, Feldchtein F, Amazeen P, Coleman N, Mitchell J. Evaluation of Radiation-Induced Oral Mucositis by Optical Coherence Tomography. Clin Cancer Res 11: 5121-5127, 2005. Muanza T, Albert P, Smith S, Godette D, Sears Crouse N, Cooley-Zgela T, Sciuto L, Camphausen K, Coleman N, Menard C. Comparing Measures of Acute Bowel Toxicity in Patients with Prostate Cancer Treated with External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys. 1;62(5):1316-21, 2005. Ervin Podgorsak W. Abdel-Rahman, J. Seuntjens, F. DeBlois, F. Verhaegen, E.B. Podgorsak, Validation of Monte Carlo-calculated surface doses for megavoltage photon beams, Med. Phys. 32, 286-298 (2005). W. Abdel-Rahman and E.B. Podgorsak, Radioactivation revisited: depletion and depletion-activation models, Med. Phys. 32, 326-336 (2005). S. Devic, J.P. Seuntjens, E. Sham, E.B. Podgorsak, R.C. Schmidtlein, A.S. Kirov, C.G. Soares, Precise radio-chromic film dosimetry using a flat-bed document scanner, Med. Phys. 32, 2245-2253 (2005). Y.Z. Wang, M.D.C. Evans, E.B. Podgorsak, Characteristics of induced activity from medical linear accel-erators, Med. Phys. 32, 2899-2910 (2005). J.P. Seuntjens, M.D.C. Evans, M. Olivares, E.B. Podgorsak, Absorbed dose to water reference dosimetry using solid phantoms in the context of absorbed-dose protocols, Med. Phys. 32, 2945-2953 (2005). T. Vuong, S. Devic, B. Moftah, M.D.C. Evans, E.B. Podgorsak, High-dose rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: Technical aspects, Brachytherapy 4, 230-235 (2005). 13
  • Department of Oncology Appendix II: Publications January-December 2005 Invited book chapters E.B. Podgorsak, Basic Radiation Physics, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 1, pp. 1-43, edited by E.B. Podgorsak, International Atomic Energy Agency, Vienna, Austria (2005). E.B. Podgorsak, Treatment Machines for External Beam Radiation Therapy, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 5, pp. 123-160, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). E.B. Podgorsak, Physical Aspects of External Photon Beams, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 6, pp. 161-217, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). P. Andreo, J.P. Seuntjens, and E.B. Podgorsak, Calibration of Photon and Electron Beams, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 9, pp. 301-353, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). N. Suntharalingam, E.B. Podgorsak, H. Tolli, Brachytherapy: Physical and Clinical Aspects, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 13, pp. 451-483, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). N. Suntharalingam, E.B. Podgorsak, Basic Radiobiology, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 14, pp. 485-504, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). E.B. Podgorsak, M.B. Podgorsak, Special Techniques in Radiation Therapy, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 15, pp. 505-548, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). P. Ortiz-Lopez, G. Rajan, E.B. Podgorsak, Radiation Protection and Safety in Radiotherapy, in “Review of Radiation Oncology Physics: A Handbook for Teachers and Students”, Chapter 16, pp. 549-609, edited by E.B. Podgorsak, International Atomic Energy Agency (IAEA), Vienna, Austria (2005). Conference proceedings W. Abdel-Rahman, R. Corns, M. Evans, E.B. Podgorsak, In-house leak testing with a Muli-Channel Analyzer system, Proceedings of the 51st Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Hamilton, Ontario; 7-9 July, 2005; pp. 66-68. 14
  • Department of Oncology Appendix II: Publications January-December 2005 M. Evans, F. DeBlois, W. Abdel-Rahman, R. Corns, E. Podgorsak, Boxes, locks and Talks: Making class II compliance in a regulated environment, Proceedings of the 51-st Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Hamilton, Ontario; 7-9 July, 2005; pp.135-137. W. Abdel-Rahman, E.B. Podgorsak, Neutron-activation revisited: The depletion and depletion-activation models, Proceedings of the 51st Annual Scientific Meeting of the Canadian Organization of Medical Physicists (COMP), Hamilton, Ontario; 7-9 July, 2005; pp. 182-184. George Shenouda Niazi TM, Souhami L, Sultanem K, Duclos M, Shenouda G, Freeman C. Long term results of para-aortic irradiation for patients with stage I seminoma of the testis. Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):741-4 Roberge D, Nordstrom S, Corriveau C, Gosselin M, Olivares M, Shenouda G. Treatment of medium-sized juxtapapillary melanoma with external Co-60 photon therapy. Radiotherapy & Oncology 2005; 74(1):71-73. Al-Yahya K, Schwartz M, Shenouda G, Verhaegen F, Freeman C, Seuntjens J. Energy modulated electron therapy using a few leaf electron collimator in combination with IMRT and 3D-CRT: Monte Carlo-based planning and dosimetric evaluation. Med. Phys.2005 Sept;32(9) 2976-86. Luis Souhami Publications written by a student/resident under my direct supervision are shown with a dot •) Souhami L, Corns R, Duclos M, Portelance L, Bahoric B, Stanimir G. Long-term results of high dose rate brachytherapy in cervix cancer using a small number of fractions. Gynecol Oncol 97:508-513, 2005. Roberge, D, Corns R, Souhami L. Prostate and seminal vesicle displacement following urethrography: a computed tomography-based study. Cancer Radiother. 9:148-151, 2005. Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 63: 37-46, 2005. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 63:47-55, 2005. 15
  • Department of Oncology Appendix II: Publications January-December 2005 Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg, Ayoub J, Smith C, Souhami L, Hamburg S, Spanos W, Kreisman H, Boyd AP, Cagnoni PJ, Curran WJ. Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non-Small- Cell Lung Cancer. J Clin Oncol. 23:5918-5928, 2005. •Niazi, TM, Souhami L, Portelance, L, Bahoric, B, Gilbert, L, Stanimir, G. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys 63:1108-1113, 2005. Frank Verhaegen W. Abdel-Rahman, J. Seuntjens, F. Verhaegen, F. Deblois, E. Podgorsak. Validation of Monte Carlo calculated surface doses for megavoltage photon beams. Med. Phys., 32, 286-98, 2005. E. Poon*, J. Seuntjens, F. Verhaegen. Consistency test of the electron transport algorithm in the GEANT4 Monte Carlo code . Phys. Med. Biol., 50, 681-94, 2005. V. Huang*, J. Seuntjens, S. Devic, F. Verhaegen. Experimental determination of electron source parameters for accurate Monte Carlo calculation of large field electron therapy. Phys. Med. Biol., 50, 779-786, 2005 J. Seco*, E. Adams., M. Bidmead., M. Partridge., F. Verhaegen. Head & Neck IMRT treatments assessed with a Monte Carlo dose calculation engine. Phys. Med. Biol., 50, 817-830, 2005. K. Al-Yahya., D. Hristov, F. Verhaegen, J. Seuntjens. Inverse Monte Carlo based modulated electron beam treatment planning based on a few leaf electron collimator – feasibility study. Phys. Med. Biol., 50, 847-857, 2005. F. Verhaegen, S. Devic. Sensitivity study for CT image use in Monte Carlo Treatment Planning. Phys. Med. Biol., 50, 937-946, 2005. H. Palmans, F. Verhaegen. Assigning nonelastic nuclear interaction cross sections to Hounsfield Units for Monte Carlo treatment planning of proton beams. Phys. Med. Biol. , 50, 991-1000, 2005 J. Belec*, H. Patrocinnio, F. Verhaegen. Development of a Monte Carlo model for the Brainlab microMLC. Phys. Med. Biol. , 50, 787-799, 2005. E. Poon*, F. Verhaegen. Accuracy of the photon and electron physics in GEANT4 for radiotherapy applications. Med. Phys., 32, 1696-1711, 2005. 16
  • Department of Oncology Appendix II: Publications January-December 2005 F. Verhaegen, B. Reniers, F. Deblois, S. Devic, J. Seuntjens, D. Hristov. Dosimetric and microdosimetric study of contrast-enhanced radiotherapy with kilovolt x-rays. Phys. Med. Biol. , 50, 3555-3569, 2005. Flampouri S*, McNair H A, Donovan E M, Evans P M, Partridge M, Verhaegen F, Nutting C M. Initial patient imaging with an optimised radiotherapy beam for portal imaging. Radiother. Oncol, 76, 63-71, 2005. S. Lehnert, B. Reniers, F. Verhaegen. Relative biological efficiency in terms of tumor response of 125-I implants compared with 60-Co gamma rays. Int. J. Rad. Oncol. Biol. Phys., 63, 224-229, 2005 K. Al-Yahya, M. Schwartz, G. Shenouda, F. Verhaegen, C. Freeman, J. Seuntjens. Energy modulated electron therapy using a few leaf electron collimator in combination with IMRT and 3D-CRT: Monte carlo based planning and dosimetry. Med. Phys., 32, 2976-86, 2005 G. Jarry* and F. Verhaegen. Electron Beam Treatment Verification Using Measured and Monte Carlo Predicted Portal Images. Phys. Med. Biol., 50, 4977-94, 2005 Te Vuong Foote R, Eeidner J, Harris N, Hammond E, Lewis J, Vuong T, Ang K, Fu K. Evaluation of tumor Angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: Results of RTOG 9505. Int J Radiat Oncol Biol Phys 2005;61:745-53. Devic S, Vuong T, Moftah B. Advantages of the multichannel endorectal applicator during high dose rate endorectal brachytherapy treatment of patients with locally advanced rectal cancer. J Applied Clin Med Phys 2005;6:44-49. Vuong T, Devic S, Moftah B, Evans M, Podgorsak EB. High dose rate endorectal brachytherapy in the treatment of locally advanced rectal carcinoma: Technical aspects. Brachytherapy 2005;4:230-235. Vuong T, Szego P, David M, Parent J, Mayrand S, Corns R, Burtin P, Evans M. Devic S. The safety and usefulness of high dose rate endoluminal brachytherapy as a boost in the treatment of patients with esophagus cancer with external beam radiation with or without chemotherapy. Int J Radiat Oncol Biol Phys 2005; 63:758-764. Division of Cancer Epidemiology Eduardo Franco Sichero L, Franco EL, Villa LL(*). Different p105 promoter activities among natural variants of human papillomavirus type 18. Journal of Infectious Diseases 191: 739-742, 2005. 17
  • Department of Oncology Appendix II: Publications January-December 2005 Spence A(§), Franco E, Ferenczy A(*). The role of human papillomaviruses in cancer: evidence to date. American Journal of Cancer 4: 49-64, 2005. Richardson H(§), Abrahamowicz M, Tellier P, Kelsall G, du Berger R, Ferenczy A, Coutlée F, Franco EL(*). Modifiable risk factors associated with clearance of type- specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiology Biomarkers & Prevention 14: 1149-1156, 2005. Coutlée F(*), Rouleau D, Ferenczy A, Franco E. The laboratory diagnosis of genital human papillomavirus infections. Canadian Journal of Infectious Diseases and Medical Microbiology 16: 83-91, 2005. Koushik A(§), Ghosh A, Duarte-Franco E, Forest P, Voyer H, Matlashewski G, Coutlée F, Franco EL(*), for the Biomarkers of Cervical Cancer Risk (BCCR) Study Team. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detection and Prevention 29: 307-316, 2005. Kowalski LP(§*), Nishimoto IN, Carvalho AL, Oliveira BV, Curado MP, Fava AS, Torloni H, Franco EL. Looking beyond tobacco and alcohol: The role of lifestyle and other environmental risk factors for laryngeal cancer. Applied Cancer Research 25: 10- 19, 2005. Franco EL, Harper DM. Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine 23: 2388-2394, 2005. Lau S(§), Franco EL(*). Management of low-grade cervical lesions in young women. Canadian Medical Association Journal 173: 771-774, 2005. Duarte-Franco E, Franco EL(*). Cancer of the Colon and Rectum: Epidemiology and Risk factors. In: Rossi BM (ed.) Cancer of the Colon, Rectum and Anus, Lemar and Tecmedd, Sao Paulo, 2005, pp. 3-22, ISBN 858665303-9. Duarte-Franco E, Franco EL(*). Cancer of the Anus: Epidemiology and Risk Factors. In: Rossi BM (ed.) Cancer of the Colon, Rectum and Anus, Lemar and Tecmedd, Sao Paulo, 2005, pp. 665-678, ISBN 858665303-9. Paul Allison Nicolau B*, Marcenes W, Allison PJ & Sheiham A (2005). The relationship between height and dental caries in adolescents. Community Dentistry & Oral Epidemiology. 33:93-8 Hennequin M, Allison PJ, Veyrune JL, Faye M & Peyron MA (2005): Clinical evaluation of mastication: validation of video versus electromyography. Clinical Nutrition 24:314-320 Allison PJ & Lawrence HP (2005): Validity of an instrument assessing oral health in people with Down syndrome. Community Dental Health. 22(4):224-230 18
  • Department of Oncology Appendix II: Publications January-December 2005 Fung K* & Allison PJ (2005). A comparison of caries experience in individuals with Down syndrome and those without. Special Care in Dentistry. 25(6):302-10 Saub R*, Locker D, Allison PJ (2005): Derivation and validation of the short version of the Malaysian Oral Health Impact Profile. Community Dentistry & Oral Epidemiology. 33:378-83 Hennequin M, Allison PJ, Faulks D Orliaguet T, & Feine JS (2005): A comparison of chewing indicators between adults with Down syndrome and controls. Journal of Dental Research. 84(11):1057-61 Jocelyne Feine Feine J.S. and Thomason J.M. 2006. Physical Medicine in the Management of TMD Patients. In: Laskin DM, Greene CS, Hylander WL, {Eds}; TMDs An Evidenced Based Approach to Diagnosis and Treatment. Chapter 24. Quintessance Publishing. Esfandiari S., Lund J., Thomason M., Dufresne E., Kobayashi T., Dubois M., Feine JS. 2006. Can general dentists produce successful implant overdentures with minimal training ? J Dent. Accepted March 2006. Heydecke G, Penrod JR, Takanashi Y, Lund JP, Feine JS, Thomason JM. 2005. Cost- effectiveness of mandibular two-implant overdentures and conventional dentures in edentulous seniors. J Dent Res 84(9):794-799. Kawai Y, Murakami H, Shariati B, Klemetti E, Blomfeild J, Billette L, Lund JP, Feine JS. 2005.Comparing quality of complete dentures fabricated using traditional and simplified techniques. J of Dentistry. 33:659-668 Kobayashi T, Ghanem H, Umezawa K, Mega J, Kawara M, Feine JS. 2005. Treatment of Self-Inflicted Oral Trauma in Comatose Patient: A Case Report. J Can Dent Assoc. 71 (9): 663-666. Mack F, C Schwahn, JS Feine, T Mundt, Ol Bernhardt, U John, T Kocher, R Biffar. 2005. The Impact of Tooth Loss on General Health Related Quality of Life Among Elderly Pomeranians: Results from the Study of Health in Pomerania (SHIP-O). Int J Prosthodont. 18:414-419. Hennequin M, P.J. Allison, D. Faulks, T. Orliaguet, and J.S.Feine. 2005. Chewing Indicators between Adults with Down Syndrome and Controls. J Dent Res. 84:1057-106. Mark Goldberg Goldberg MS, Burnett RT. A new longitudinal design for identifying subgroups of the population who are susceptible to the short-term effects of ambient air pollution. J Toxicol. Environ Health A 2005;68(13-14), 1111-1125. 19
  • Department of Oncology Appendix II: Publications January-December 2005 Gilbert N.L., Goldberg MS, Beckerman B, Jerrett M, Brook JR. Assessing Spatial Variability of Ambient Nitrogen Dioxide in Montreal, Canada, with a Land Use Regression Model, Journal of the Air & Waste Management Association, 2005; 55:1059–1063. Krewski, D; Burnett, R; Goldberg, M; Hoover, K; Siemiatycki, J; Abrahamowicz, M; Villeneuve, P; White, W. Reanalysis of Harvard Six Cities Study, Part II. Sensitivity Analysis. Inhalation Toxicology, 2005;17(7):335-42 Krewski, D; Burnett, R; Goldberg, M; Hoover, K; Siemiatycki, J; Abrahamowicz, M; White, W. Reanalysis of Harvard Six Cities Study, Part I. Validation and Replication. Inhalation Toxicology, 2005;17(7):343-352 Goldberg MS, Tomic K, (University of Alberta), Burnett RT, Cakmak S. (Health Canada), Drouin L, Fortier I (Direction de la santé publique, Montréal-Centre). The Short-Term Effects of Weather Conditions on Daily Mortality in Montreal. Contract with Health Canada, March 2005. Goldberg MS. Associations of Weather Conditions on Daily Mortality among Persons Living in Montreal having Specific Health Conditions Before Death. Contract with Health Canada, March 2005. Monographs Institute of Medicine. Disposition of the Air Force Health Study. Interim Letter Report. Committee on the Disposition of the Air Force Health Study. Board on Population Health and Public Health Practices. National Academy Press, Washington, D.C., 2005. (NB: I was a member of this committee.) Institute of Medicine. Gulf War and Health, Volume 3: Fuels, Combustion Products, and Propellents. Committee on Gulf War and Health, Division of Health Promotion and Disease Prevention, National Academy Press, Washington, D.C., 2005 (ISBN: 0-309- 09527-1). (NB: I was a consultant for this committee and developed the sections on lung cancer.) Goldberg MS. Commentary on Bell et al. “Ozone and short-term mortality in 95 US urban communities, 1987-2000” (JAMA 2004; 292: 2372-2378). Evidence-based Healthcare & Public Health, 2005;9:206-8. Medical Oncology Sarit Assouline Gambacorti-Passerini C., Gasser M, Ahmed S., Assouline S., Scapozza L., Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.Leukemia. 2005 Jul; 19(7):1267-9. 20
  • Department of Oncology Appendix II: Publications January-December 2005 Gerald Batist Lapointe R, Letourneau R, Steward W, Hawkins RE, Batist G, Vincent M, Whittom R, Eatock M, Jolivet J, Moore M., Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: Gastrointestinal tumors. Ann Oncol. 2005 Feb;16(2):289-93. Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 2005 Mar;23(2):147-55 Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller Jr WH, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (Iressatrade mark) 750 mg per day, an oral epidermal growth factor receptor- tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs. 2005 Jan;23(2):165-70. Miao W, Hu L, Scrivens PJ, Batist G. Transcriptional regulation of NRF2 expression by the AHR-XRE signaling pathway: Direct cross-talk between phase I and II drug- metabolizing enzymes. J Biol Chem. 2005 May 27;280(21):20340-8. Epub 2005 Mar 23 Dent SF, Arnold A, Stewart DJ, Gertler S, Ayoub J, Batist G, Goss G, Nevile A, Soulieres D, Jolivet J, McLntosh L, Seymour L. Phase II study of troxacitabine (BCH- 4556) in patients with advanced non-small-cell lung cancer. Lung. 2005 Jul- Aug;183(4):265-72. Hamilton D, Batist G. TLK-199 (Telik). IDrugs.2005 Aug: 8(8):662-9 Chen EX, Batist G, Siu LL, Bangash N, Maclean M, McIntosh L, Miller WH Jr, Oza AM, Lathia C, Petrenciuc O, Seymour L. Phase I and pharmacokinetic study of Bay 38- 3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. Invest New Drugs. 2005 Oct;23(5):455-65. Haidara K, Zamir L, Shi QW, Batist G. The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Letters, 2005 Dec 29 Book Chapter Batist G., Hamilton D, 22nd Annual of Cancer Chemotherapy & Biological Response Modifiers, Elsevier Press, 2005, Chapter 2 [22:19-33].: Anthracyclines 21
  • Department of Oncology Appendix II: Publications January-December 2005 Vera Hirsh Hirsh V, Latreille J, Kreisman H, Desjardins P, Ofiara L, Whittom R, Fox S, Palayew MD, and Pintos J: Sequential Therapy with Vinorelbine Followed by Gemcitabine in Patients with Metastatic Non Small Cell Lung Cancer (NSCLC), Performance Status (PS) 2, or Elderly with Comorbidities – A Multicenter Phase II Trial. Lung Cancer, Vol. 49(1): 117-123, July 2005. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, and Seymour L: Erlotinib in previously treated non-small-cell lung cancer: National Cancer Institute of Canada Clinical Trials Group. New Engl J Med, Vol. 353(2): 123-132, July 2005. Brian Leyland-Jones Burger A, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. Essential Roles of IGFBP-3 and IGFBP-rPI in Breast Cancer. Eur J Cancer. Vol.41:1515-1527, 2005. Leyland-Jones B , Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X and Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23(25):5960-72, 2005. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, et al., for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659-72, 2005. Wilson Miller MacKenzie M, Hirte H, Goss G, Maroun J, Goel R, Major P, Miller WH Jr, Panasci L, Lorimer I, Batist G, Mattews S, Douglas L, Seymour L. A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs, 23:165-170, 2005. Del Rincon S, Guo Q, Morelli C, Shiu H, Surmacz E, Miller WH Jr. Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC- dependant mechanism. Oncogene 23: 9269-79, 2004. Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, HM Schipper, Miller WH Jr. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood, 105:1237-1245, 2005. 22
  • Department of Oncology Appendix II: Publications January-December 2005 Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, McNamara S, Miller WH Jr, Lo Coco F, Pelicci PG, Nervi C. Retinoic targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene, 24:1820-1830, 2005. Diaz Z, Assaraf MI, Miller WH Jr, and Schipper HM. Astroglial cytoprotection by erythropoietin preconditioning: implications for ischemic and degenerative CNS disorders. Journal of Neurochemistry, 93:392-402, 2005. Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs, 23:147-55, 2005. Mann KK, Padovani AMS, Guo Qi, Colosimo AL, Lee HY, Kurie JM, Miller WH Jr. Arsenic trioxide inhibits nuclear receptor function via JNK-mediated RXR phosphorylation. J Clin Invest, 115: 2924 - 2933, 2005. Lawrence Panasci Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller Jr WH, Panasci LC, Lorimer IA, Batist G, Matthews S, Douglas L and Seymour L. A phase II trial of ZD1839 (Iressatrade mark) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs Jan;23(2):165-70, 2005. Aloyz R and Panasci LC. Reply to ‘Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4’ by Chow et al. Leukemia Apri 7, 2005. Xu Z, Loignon M, Han F, Panasci LC, and Aloyz R. XRCC 3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase check point activation, and reduced apoptosis. J Pharmacol Exp Ther April 20, 2005. Nguyen TH, Ong CK, Wong E, Leong CT, Panasci LC and Huynh H. 2-Chloroethyl-2- sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and –independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo. Int J Oncol 27(4):1131-40, 2005 Cesaire R, Oliere S, Shaif-Askari E, Loignon M, Lezin , Olindo S, Panelatti G, Kzanji M, Aloyz R, Panasci LC, Bell JC and Hiscott J. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene Sept 2005. 23
  • Department of Oncology Appendix II: Publications January-December 2005 Nursing Oncology Linda Edgar Pepler, C., Edgar L., Frisch S., White, C., and Rennick J. (2005) Strategies to increase research-based practice: Interplay with unit culture. Clinical Nurse Specialist. 20(1) 23- 34. Lee, V., Cohen R, Edgar L, Laizner A. and Gagnon A. (2005) Development and preliminary evaluation of a meaning –making intervention for cancer.patients. Oncology Nursing Forum. Lee, V., Cohen R, Edgar L, Laizner A. and Gagnon A. (2005). Meaning-making intervention during breast or colo-rectal cancer treatment. Social Science in Medicine. Pepler, C., Edgar L., Frisch S., White, C., and Rennick J. (2005) Unit culture and research based nursing practice in acute care. Canadian J. of Nursing Research. 37 (3). Carmen Loiselle Loiselle, C. G., Semenic, S., & Côté, B. (2005). Sharing empirical knowledge to improve breastfeeding promotion and support: Description of a research dissemination project. Worldviews on Evidence-Based Nursing, 2(1), 25-32. Paper that also has been retained as examplar publication and placed on the journal's website. Loiselle, C. G. (2005). Nursing taking the lead in psychosocial oncology research training. Canadian Oncology Nursing Journal, 15(4), 260-261. Lambert, D. S. & Loiselle, C. G. (2005). Refinement of a questionnaire to assess individuals' patterns of health information-seeking behaviour. Canadian Oncology Nursing Journal, 15(4), 262-263. Palliative Care Robin Cohen *Macdonald ME, Liben S, Carnevale FA, Rennick JE, Wolf SL, Meloche D, Cohen SR. Parental perspectives on hospital staff acts of kindness and commemoration after a child’s death. Pediatrics, 2005; 116: 884-890. *Ahmed S, Mayo NE, Wood-Dauphinee S, Hanley J, Cohen SR. Using the Patient- Generated Index to evaluate response shift post-stroke. Quality of Life Research, 2005; 14: 2247-2257. Surgical Oncology Armen Aprikian Alvarado C, Beitel LK, Sircar K, Aprikian AG, Trifiro M, Gottlieb B. Somatic mosaicism and cancer: A micro-genetic examination into the role of the androgen receptor in prostate cancer. Cancer Research, 65:8514-8518, 2005 24
  • Department of Oncology Appendix II: Publications January-December 2005 Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. Journal of Urology, 173:1930-4, 2005 Mark Basik Salvucci O, Bouchard A, Baccarelli A, Bianchi R, Deschenes J, Simon R, Sauter G, Basik M. The role of the CXCR4 receptor in progression and prognosis in breast cancer. Proceedings AACR Annual Meeting 2005. abstract 5604. Garrett C, Takimoto C, Wojtowicz M, Burris H, Hidalgo M, Tan B, Krishnamurthi S, Basik M, Baselga J, Mauro D. Identification of a Molecular Signature of radiographic Response to Cetuximab in Patients with Advanced Colorectal Cancer. Proceedings ASCO 2005, poster # 3626. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer : a large tissue microarray study. Breast Cancer Research & Treatment, Dec 2005, Dec 13;:1-9 epub. Martin Black and Michael Hier Payne RJ, Hier MP, Tamilia M, MacNamara E, Young J, Black MJ. Same-day discharge after total-thyroidectomy: the value of 6-hour serum parathyroid hormone and calcium levels. Head & Neck. 2005:27:1:1-7. Payne RJ, Hier MP, Kost KM, Black MJ, Zeitouni AG, Frenkiel S, Naor N, Kimoff RJ. High prevalence of obstructive sleep apnea among patients with head and neck cancer. J Otolaryngol 2005:34:5:304-311. Payne RJ, Hier MP, Cote V, Tamilia M, MacNamara E, Black MJ. Postoperative parathyroid hormone levels in conjunction with corrected calcium values as a predictor of a new protocol. J Otolaryngol 2005:34:5:323-327. Payne RK, Young J, Hier MP, Black MJ. Benefits resulting from 1- and 6-hour parathyroid hormone and calcium levels after thyroidectomy. Otolaryngol Head Neck Surg 2005:133:3:386-390. Philip Gordon Gordon PH. Anatomy and Physiology of the Anorectum. In: Current Therapy in Colon and Rectal Surgery. 2nd Ed. Eds Fazio VW, Church JM, Delaney CP. Elsevier Mosby. Philadelphia 2005:1-9. Morin NA, Gordon PH. Neoplasms of the colon and Rectum. In: Conn’s Current Therapy Eds Rakel RE, Bope ET. Elsevier Saunders 2005:641-8. 25
  • Department of Oncology Appendix II: Publications January-December 2005 Gordon PH, Moreno Elola-Olaso A. Manejo de la enfermeded de Crohn perianal. In : Actualización en cirugiá del aparato Digestivo Vol XI. Ed. E Moreno González Jarpyo Editores SA Fundación MMA. Madrid, Spain 2005:167-171. Gordon PH. Detección precoz del carcinoma colorrectal. In : Actualización en cirugiá del aparato Digestivo Vol XI. Ed. E Morenno González Jarpyo Editores SA Fundación MMA. Madrid, Spain 2005:217-229. Gordon PH, Moreno Elola-Olaso A. Estudio genético y carcinoma colorrectal hereditario. In: Actualización en cirugiá del aparato Digestivo Vol XI. Ed. E Moreno González Jarpyo Editores SA Fundación MMA. Madrid, Spain 2005:231-235. Gordon PH, Moreno Elola-Olaso A. Carcinoma del canal anal. In : Actualización en cirugiá del aparato Digestivo Vol XI. Ed. E Moreno González Jarpyo Editores SA Fundación MMA. Madrid, Spain 2005:273-280. Gordon PH, Moreno Elola-Olaso A. Adenomas de colon como indicador par la realización de colonscopia completa. In : Actualización en cirugiá del aparato Digestivo Vol XI. Ed. E Moreno González Jarpyo Editores SA Fundación MMA. Madrid, Spain 2005:281-285. Gordon PH, Moreno Elola-Olaso A. Trat a miento quiurgico electivo en la enfermedad diverticular de colon. In : Actualización en cirugiá del aparato Digestivo Vol XI. Ed. E Moreno González Jarpyo Editores SA Fundación MMA. Madrid, Spain 2005:333-338. Walter Gotlieb Machtinger R, Gotlieb WH, Korach J, Fridman E, Apter S, Goldenberg M, Ben-Baruch G. Placental site trophoblastic tumor: outcome of five cases including fertility preserving management. Gynecologic Oncology (2005)96: 56–61 Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, Modan B, and Ben-Baruch G. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecologic Oncology (2005)97: 780-783 Pathak B, Bruchim I, Brisson ML, Hammouda W, Bloom C, and Gotlieb WH Granulocytic Sarcoma presenting as tumours of the cervix Gynecologic Oncology (2005) 98: 493-497 Wiser A, Korach J, Gotlieb WH, Fridman E, Apter S, and Ben-Baruch G. Importance of accurate preoperative diagnosis in the management of aggressive angiomyxoma: report of three cases and review of the literature. Abdominal Imaging Epub Nov 28, 2005 26
  • Department of Oncology Appendix II: Publications January-December 2005 Conference Proceedings: Gotlieb WH, Gu J, Bruchim I, Shi Y, Camirand A, Blouin MJ, Pollak MN Insulin-like growth factor I receptor (IGF-IR) targeting in epithelial ovarian cancer. Society of Gynecologic Oncology Meeting, Miami March 2005 Gotlieb WH, Bruchim I, Ben-Baruch G, Davidson B, Zeltser A, Andersen A, Olsen H. Doxorubicin levels in the serum and ascites following intravenous administration in patients with ovarian cancer. Society of Gynecologic Oncology Meeting, Miami March 2005 Gotlieb WH, Israeli O, Bruchim I, Salaheddin MS, Aviram-Goldring A, Rienstein S, Friedman E, Ben-Baruch G. Correlation between genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma Society of Gynecologic Oncology Meeting, Miami March 2005 A.M. Oza, L.Elit, J. Biagi, W.Gotlieb, K Tonkin, M. Tsao, D. Hedley, C. Hansen, J. Dancey, E. Eisenhauer, L. Seymour. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer – NCIC CTG IND 160 Richard Margolese Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of Clincal Oncology 97:22: 1652-1662, 2005 Nov.16. Hani Shennib Hani Shennib, Jeffrey Bogart, James E. Herndon, II, Leslie Kohman, Robert Keenan, Mark Green, David Sugarbaker The Cancer and Leukemia Group B and The Eastern Cooperative Oncology Group.Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: The Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J. Thorac. Cardiovasc. Surg., 2005; 129: 813 - 818. Hani Shennib and Osama Benhameid Sequential Subxyphoid and Thoracotomy Incisions With Graft Pull Through for Targeted Redo Multivessel Surgical Revascularization. Ann. Thorac. Surg., 2005; 80: 350 - 352. Simon Tanguay Cury FL, Souhami L, Rajan R, Tanguay S, Gagnon B, Duclos M, Shenouda G, Faria SL, David M, Freeman CR. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2005 27
  • Department of Oncology Appendix II: Publications January-December 2005 Nickel JC, Herschorn S, Corcos J, Donnelly B, Drover D, Elhilali M, Goldenberg L, Grantmyre J, Laroche B, Norman R, Piercy B, Psooy K, Steinhoff G, Trachtenberg J, Saad F, Tanguay S; Canadian Prostate Health Council; Canadian Urological Association Guidelines Committee. Canadian guidelines for the management of benign prostatic hyperplasia. Can J Urol., 12: 2677, 2005. Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol., 173: 1930, 2005. Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin Cancer Res., 11: 1302, 2005 Pathology Tarek Bismar Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA: Prognostic factors in lymph node-positive prostate cancer. Urology 2006, 67:1016-1021 Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, Bismar TA, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA: Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006, 66:1037-1043 Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA: Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006, 8:59-68 Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, Kantoff PW, Johansson JE: Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005, 14:1424-1432 Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M: A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005, 24:4736-4740 28